VITRO BIOPHARMA, INC. Financial Statements (2026 and earlier)
Company Profile
| Business Address |
3200 CHERRY CREEK DRIVE SOUTH DENVER, CO 80209 |
| State of Incorp. | NV |
| Fiscal Year End | October 31 |
| Industry (SIC) | 2836 - Biological Products, Except Diagnostic Substances (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)
| 7/31/2025 MRQ | 1/31/2025 MRQ | 10/31/2024 | 10/31/2023 | 10/31/2015 | 10/31/2014 | 10/31/2013 | |||
|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||
| Current Assets | |||||||||
| Cash, cash equivalents, and short-term investments | 114 | 571 | 102 | 5 | 3 | 2 | |||
| Cash and cash equivalent | 114 | 571 | 102 | 5 | 3 | 2 | |||
| Receivables | (1) | 206 | 120 | 10 | 19 | ||||
| Inventory, net of allowances, customer advances and progress billings | 161 | 115 | 171 | 29 | 22 | 25 | |||
| Inventory | 161 | 115 | 171 | 29 | 22 | 25 | |||
| Prepaid expense | 100 | 83 | 131 | 0 | |||||
| Deferred costs | 2,656 | ||||||||
| Other undisclosed current assets | 37 | 5 | 3 | 5 | |||||
| Total current assets: | 409 | 976 | 3,179 | 49 | 47 | 33 | |||
| Noncurrent Assets | |||||||||
| Finance lease, right-of-use asset, after accumulated amortization | 2 | 3 | 33 | ✕ | ✕ | ✕ | |||
| Operating lease, right-of-use asset | 315 | 346 | 476 | ✕ | ✕ | ✕ | |||
| Property, plant and equipment | 102 | 140 | 320 | 44 | 42 | 11 | |||
| Intangible assets, net (including goodwill) | 3,522 | 3,530 | 4,277 | 12 | 15 | 18 | |||
| Goodwill | 3,172 | 3,172 | 3,609 | ||||||
| Intangible assets, net (excluding goodwill) | 350 | 358 | 668 | 12 | 15 | 18 | |||
| Regulated entity, other noncurrent assets | 170 | ||||||||
| Other noncurrent assets | 8 | 8 | 8 | 1 | |||||
| Other undisclosed noncurrent assets | 88 | 86 | 49 | 11 | 1 | (156) | |||
| Total noncurrent assets: | 4,037 | 4,113 | 5,164 | 67 | 59 | 43 | |||
| TOTAL ASSETS: | 4,447 | 5,089 | 8,344 | 116 | 106 | 76 | |||
| LIABILITIES AND EQUITY | |||||||||
| Liabilities | |||||||||
| Current Liabilities | |||||||||
| Accounts payable and accrued liabilities | 4,302 | 3,970 | 28 | 1,278 | 1,256 | 28 | |||
| Employee-related liabilities | ✕ | ✕ | ✕ | ✕ | 1,206 | 1,206 | |||
| Accounts payable | 2,443 | 2,164 | 64 | 48 | 28 | ||||
| Accrued liabilities | 1,859 | 1,806 | 28 | 8 | 2 | ||||
| Deferred revenue | 525 | 525 | 525 | ✕ | ✕ | ✕ | |||
| Debt | 4,224 | 4,731 | 1,309 | 8 | 23 | ||||
| Deferred compensation liability | 1,203 | ||||||||
| Derivative instruments and hedges, liabilities | 149 | 155 | |||||||
| Due to related parties | ✕ | ✕ | ✕ | ✕ | 34 | 30 | |||
| Other undisclosed current liabilities | 3,460 | 681 | 2,987 | 1,174 | 779 | ||||
| Total current liabilities: | 12,661 | 10,063 | 4,850 | 2,495 | 1,309 | 2,010 | |||
| Noncurrent Liabilities | |||||||||
| Long-term debt and lease obligation | 1,094 | 3,055 | 2,968 | ||||||
| Long-term debt, excluding current maturities | 1,092 | 3,050 | 2,951 | ||||||
| Finance lease, liability | 2 | 5 | 17 | ✕ | ✕ | ✕ | |||
| Liabilities, other than long-term debt | 324 | 353 | 1,239 | ||||||
| Operating lease, liability | 198 | 227 | 346 | ✕ | ✕ | ✕ | |||
| Derivative instruments and hedges, liabilities | 126 | 126 | 893 | ||||||
| Other undisclosed noncurrent liabilities | 277 | 620 | 377 | 3 | (1,953) | ||||
| Total noncurrent liabilities: | 1,695 | 4,027 | 4,585 | 3 | (1,953) | ||||
| Other undisclosed liabilities | 957 | ||||||||
| Total liabilities: | 14,356 | 14,090 | 9,435 | 2,498 | 2,266 | 56 | |||
| Equity | |||||||||
| Equity, attributable to parent, including: | (9,909) | (9,001) | (1,091) | (2,382) | (2,160) | (1,933) | |||
| Preferred stock | |||||||||
| Common stock | 4 | 4 | 4 | 20 | 20 | ||||
| Treasury stock, value | (84) | (84) | (84) | ||||||
| Additional paid in capital | 30,954 | 29,028 | 27,065 | 5,456 | 5,433 | 5,413 | |||
| Accumulated deficit | (40,784) | (37,950) | (28,076) | (7,859) | (7,613) | (7,366) | |||
| Other undisclosed equity, attributable to parent | 20 | ||||||||
| Equity, attributable to noncontrolling interest | (1,933) | ||||||||
| Other undisclosed equity | 3,887 | ||||||||
| Total equity: | (9,909) | (9,001) | (1,091) | (2,382) | (2,160) | 20 | |||
| TOTAL LIABILITIES AND EQUITY: | 4,447 | 5,089 | 8,344 | 116 | 106 | 76 | |||
Income Statement (P&L) ($ in thousands)
| 7/31/2025 TTM | 1/31/2025 TTM | 10/31/2024 | 10/31/2023 | 10/31/2015 | 10/31/2014 | 10/31/2013 | ||
|---|---|---|---|---|---|---|---|---|
| Revenues | 1,881 | 1,856 | 1,763 | 78 | 120 | 23 | ||
| Revenue, net | ✕ | ✕ | ✕ | ✕ | 99 | 95 | 23 | |
| Cost of revenue (Cost of Product and Service Sold) | (434) | (426) | (298) | (22) | (23) | |||
| Other undisclosed gross profit | 7 | (25) | (3) | |||||
| Gross profit: | 1,447 | 1,429 | 1,465 | 63 | 72 | 20 | ||
| Operating expenses | (7,571) | (7,926) | (6,847) | (236) | (399) | (229) | ||
| Other undisclosed operating income (loss) | (2,657) | 15 | 156 | 58 | ||||
| Operating loss: | (6,124) | (9,153) | (5,382) | (158) | (171) | (151) | ||
| Interest and debt expense | (2,509) | (3,502) | (270) | (88) | 75 | (60) | ||
| Loss from continuing operations before equity method investments, income taxes: | (8,632) | (12,655) | (5,652) | (246) | (96) | (211) | ||
| Other undisclosed loss from continuing operations before income taxes | (151) | |||||||
| Loss from continuing operations: | (8,632) | (12,655) | (5,652) | (246) | (247) | (211) | ||
| Loss before gain (loss) on sale of properties: | ✕ | ✕ | ✕ | ✕ | (246) | (247) | (211) | |
| Net loss: | (8,632) | (12,655) | (5,652) | (246) | (247) | (211) | ||
| Other undisclosed net income attributable to parent | 493 | 2,781 | 295 | |||||
| Net loss attributable to parent: | (8,139) | (9,874) | (5,357) | (246) | (247) | (211) | ||
| Other undisclosed net loss available to common stockholders, basic | ||||||||
| Net loss available to common stockholders, diluted: | (8,139) | (9,874) | (5,357) | (246) | (247) | (211) | ||
Comprehensive Income ($ in thousands)
| 7/31/2025 TTM | 1/31/2025 TTM | 10/31/2024 | 10/31/2023 | 10/31/2015 | 10/31/2014 | 10/31/2013 | ||
|---|---|---|---|---|---|---|---|---|
| Net loss: | (8,632) | (12,655) | (5,652) | (246) | (247) | (211) | ||
| Comprehensive loss, net of tax, attributable to parent: | (8,632) | (12,655) | (5,652) | (246) | (247) | (211) | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.